Nitrofur SR

Quick links to important sections

Nitrofur SR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrofur SR

Property Description
Active ingredient Nitrofurantoin
Form Oral Capsule (Sustained-Release)
Pharmacological class Antibacterial agent (Nitrofuran derivative)
Common use Localized elimination of uropathogens
Origin Synthetic Compound

Nitrofur SR: Definition and Pharmacological Classification

Nitrofur SR is a medication containing the single active ingredient Nitrofurantoin, a synthetic compound that is chemically classified as a Nitrofuran derivative. This agent is identified as a targeted antibacterial drug that functions by interfering with essential biological processes within susceptible bacteria. Unlike many broad-spectrum antibiotics, Nitrofurantoin is characterized by its localized action, achieving high concentrations specifically in the urine after oral administration. This unique property of highly concentrated urinary excretion is widely clinically recognized as the key mechanism for its focused therapeutic role.

What Does the Sustained-Release (SR) Capsule Form Mean?

The inclusion of "SR" denotes a Sustained-Release Formulation, meaning the medicine is an oral hard gelatin capsule engineered to control the rate at which the active Nitrofurantoin is made available in the body. This pharmaceutical design incorporates the ingredient in specific crystalline forms which dissolve gradually, preventing rapid absorption. The controlled, slow-release mechanism is intended to provide a steady, prolonged exposure of the antibacterial agent in the urine, maximizing the duration of effective concentration against uropathogens. This type of sustained delivery is often the preferred form for maintaining consistent drug levels.

General Purpose of Nitrofurantoin

The general purpose of Nitrofurantoin is to treat bacterial infections by actively eliminating microorganisms within the urinary system. The medication achieves a high local concentration, functioning as a bactericidal (bacteria-killing) agent. The unique chemical structure of the compound allows it to be rapidly filtered by the kidneys, which enables the concentration of the drug to remain highly effective at the infection site. This confirms the drug's specialized role in effectively suppressing bacterial proliferation specifically in the urine, which is its primary therapeutic goal.

What side effects are possible with Nitrofur SR?

Possible side effects and safety information

Official regulatory documents classify the possible adverse effects of Nitrofur SR (Nitrofurantoin) by frequency and affected organ system. The most Common adverse reactions typically involve the Gastrointestinal disorders class and include nausea, vomiting (emesis), and flatulence. Headache is also commonly reported. Rarer reactions classified as Very Common in some sources include temporary alopecia (hair loss) and the presence of superinfections by resistant organisms in the genitourinary tract.


Serious Adverse Reactions and Systemic Safety

The safety profile highlights the potential for rare but serious toxicities involving major physiological systems. Officially documented serious adverse reactions include potentially fatal Pulmonary Toxicity (acute, subacute, and chronic pulmonary reactions), severe Hepatotoxicity (liver damage, including hepatic necrosis and chronic active hepatitis), and Peripheral Neuropathy, which can become irreversible. These reactions are classified within the Respiratory, Hepatobiliary, and Nervous system disorders classes, respectively.


Population-Specific Safety Constraints

The medicine is subject to specific constraints based on patient characteristics and exposure duration. It is contraindicated in individuals with significant renal impairment (creatinine clearance less than 60 mL/minute) due to the risk of increased toxicity. Warnings also apply to older adults, who have an increased susceptibility to chronic pulmonary and severe hepatic reactions. Furthermore, the drug is contraindicated in neonates (infants under one month) and in pregnant patients at term (38–42 weeks gestation). The risk of chronic pulmonary and hepatic toxicities is generally associated with long-term exposure, typically defined as treatment lasting six months or longer.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose of Nitrofur SR (nitrofurantoin) primarily through acute manifestations and the potential for severe, systemic toxicity. Acute overdosage is initially characterized by gastrointestinal distress, specifically nausea, vomiting, and anorexia. Other documented signs may include vertigo and headache.


Serious Toxicities and Emergency Actions

Nitrofurantoin overdose carries the risk of life-threatening or irreversible outcomes involving major organ systems. These severe reactions include pulmonary reactions (e.g., interstitial pneumonitis), hepatotoxicity (e.g., hepatic necrosis), and severe peripheral neuropathy, all of which have been cited in regulatory warnings as resulting in fatalities.

Immediate medical attention is required in the event of a suspected overdose. Official guidance mandates contacting emergency services if the individual has collapsed, is having a seizure, or has trouble breathing. The drug must be immediately discontinued upon the appearance of any severe toxic signs.

Management is limited to symptomatic and supportive treatment, as no specific antidote is documented in regulatory prescribing information. Individuals with pre-existing conditions such as impaired renal function face an enhanced risk of severe toxicity due to poor drug clearance.

Therapeutic Uses of Nitrofur SR

Main Uses of Nitrofur SR

Nitrofur SR is an antibacterial medication specifically formulated to manage infections within the urinary tract. Its primary application is the treatment of acute, uncomplicated urinary tract infections (UTIs), such as cystitis. Unlike broad-spectrum antibiotics that affect multiple systems in the body, this medication is designed to concentrate specifically in the urine, targeting the site of the infection directly.

It is effective against a variety of gram-positive and gram-negative bacteria that commonly cause urinary distress, including Escherichia coli, which is responsible for the majority of these infections.

Therapeutic Benefits

Targeted Antimicrobial Action

As a urinary tract antiseptic, Nitrofur SR works by interfering with the vital processes of bacterial cells, including protein synthesis and DNA formation. Because the active ingredient is rapidly filtered by the kidneys and excreted into the bladder, it reaches high therapeutic concentrations exactly where the bacteria are present.

Sustained Release Formulation

The "SR" in Nitrofur SR stands for sustained release. This formulation allows the active medication to be released gradually into the system. The benefit of this delivery method is the maintenance of stable medicinal levels in the urinary tract over a longer period, which supports the eradication of the bacteria while reducing the frequency of administration required.

Prevention of Recurrence

In certain clinical scenarios, this medication is used as a preventative measure for individuals who experience chronic or recurring urinary tract infections. By maintaining a controlled environment in the bladder, it helps inhibit bacterial colonization and prevents the onset of new symptomatic infections.

Eligibility and Restrictions for Use

Who can and cannot use Nitrofur SR?

Eligibility for using Nitrofur SR is strictly defined by regulatory population rules. Absolute prohibition (contraindication) is mandatory for patients with significant impairment of renal function, including anuria, oliguria, or a creatinine clearance ( CrCl) below 60 mL/min. This requirement is crucial for safe elimination.

The medicine is strictly contraindicated in infants under one month of age. For pregnant patients, use is prohibited during labor and at term (38–42 weeks gestation).

Non-eligibility also extends to individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, known hypersensitivity to nitrofurantoin, or a past history of cholestatic jaundice linked to the drug. The sustained-release formulation is typically not recommended for children under 12 years of age. Older adults must meet the same strict renal function criteria. Use requires caution for patients with existing comorbidities like diabetes mellitus or anemia, as stated in the regulatory documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nitrofurantoin, the active ingredient in Nitrofur SR, has documented interactions that can affect its absorption, efficacy, or safety.

Pharmacokinetic Interactions

  • Uricosuric drugs: Medicines like probenecid and sulfinpyrazone should be used with caution, as they inhibit the renal excretion of nitrofurantoin. This results in increased nitrofurantoin levels in the blood, which may heighten the risk of toxicity, and decreased levels in the urine, which can reduce its effectiveness in treating urinary tract infections.
  • Antacids: Specifically, antacids containing magnesium trisilicate significantly reduce both the rate and total extent of nitrofurantoin absorption from the digestive tract, thereby lowering its effectiveness. Concurrent use should be avoided.

Pharmacodynamic and Other Interactions

  • Quinolone Antibiotics: In vitro studies have shown antagonism between nitrofurantoin and quinolone antimicrobial agents, such as ciprofloxacin or levofloxacin. While the clinical significance of this finding is debated, simultaneous application is generally not recommended.
  • Agents that increase urine pH: Carbonic anhydrase inhibitors and other agents that make the urine more alkaline can decrease the antibacterial activity of nitrofurantoin.
  • Oral Typhoid Vaccine: As a broad antibacterial agent, nitrofurantoin may render the oral live attenuated typhoid fever vaccine ineffective. Vaccination should be scheduled accordingly.

Laboratory Test Interference

Nitrofurantoin may cause a false positive reaction for glucose in the urine when tests for reducing substances are performed. This does not indicate a true change in blood sugar levels.

Mechanism of Action

Mechanism of Action: How Nitrofur SR Works

Nitrofur SR functions as a prodrug that undergoes activation exclusively within susceptible bacteria. This process begins when the compound is reduced by bacterial flavoproteins (nitroreductases), which generates highly reactive electrophilic intermediates (free radicals).

This activated form initiates a broad, simultaneous molecular assault on multiple intracellular targets. It interferes with ribosomal proteins, leading to the shutdown of protein synthesis. Concurrently, it binds to and damages bacterial DNA and RNA, inhibiting genetic transcription and replication, and disrupts enzymes involved in essential central carbohydrate metabolism.

This multi-target damage cascade facilitates cellular instability that results in the cessation of microbial proliferation and viability. Due to its rapid, high-concentration excretion by the kidneys, the active antimicrobial process is anatomically restricted to the urinary tract, resulting in a localized effect on target organisms, aligning with low systemic plasma levels.

Dosage and Administration Information

The administration of Nitrofur SR (Nitrofurantoin Sustained-Release) follows specific protocols regarding how the medication is taken. The medication is formulated as a dual-release capsule intended to ensure a continuous delivery of the active ingredient.

Administration Scope

Feature Instruction
Route of administration Oral (Swallowed)
Dosing schedule Acute Uncomplicated UTI: 100 mg per dose
Timing in relation to meals Must be administered with food (meals or milk).
Frequency pattern Twice daily (every 12 hours) for acute treatment.
Course duration Fixed course of 7 days for acute uncomplicated UTI.

Procedural and Population Constraints

The 100 mg dual-release capsule must be swallowed whole and should not be crushed, opened, or chewed, as doing so would compromise the controlled-release mechanism. This regimen is generally for patients 12 years of age and older.

An administration constraint is the prohibition of use in patients with significant renal impairment, generally defined by a Creatinine Clearance (CrCl) below 60 mL/min or an Estimated Glomerular Filtration Rate (eGFR) below 45 mL/min/1.73 m^2.

If a scheduled dose is missed, the dose should be taken as soon as remembered. However, if it is nearly time for the subsequent dose, the missed dose should be omitted and the normal, twice-daily schedule resumed without taking a double dose. These instructions establish a standardized approach to usage, defining the method, frequency, duration, and conditions required for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitrofur SR

## Clinical Evidence for Treating Acute, Uncomplicated UTIs

Research involving the active ingredient of Nitrofur SR examined its use in acute, uncomplicated urinary tract infections, a condition associated with acute or disruptive episodes such as cystitis. This research is primarily based on randomized controlled trials (RCTs) and systematic reviews that compared the active ingredient against placebo or other standard antibacterial agents. These studies were conducted during periods of increased symptom activity and typically involved short observation times.

Researchers examined several outcomes related to physical discomfort and the presence of bacteria. Studies reported measurements of both symptom relief and microbiological changes; findings describe patterns observed in the studies related to short-term changes in both symptom scores (Clinical Cure/Resolution) and uropathogen counts (Microbiological Cure). The overall evidence base for this indication includes a large number of available studies, but many of these foundational trials are older and used varying outcome criteria, which can affect the overall consistency of the combined data.

## Research Supporting Prevention of Recurrent Infections

Research has also explored the role of the active ingredient in patients experiencing conditions characterized by fluctuating or episodic manifestations, specifically focusing on the prevention of recurrent UTIs. RCTs in this area compared the continuous use of the active ingredient against a placebo or alternative medications.

Research examined outcomes related to episodic or acute changes, primarily focusing on the frequency and rate of new, symptomatic infections. These long-term studies monitored the rate of recurrence over months. Findings describe patterns observed in the studies where the rate of recurrence was observed in some studies to be lower in groups receiving continuous administration compared to comparator groups. These studies contribute to the broader evidence landscape regarding prophylactic use.

## Long-Term Research and Durability of Study Outcomes

The available evidence from RCTs for treatment of acute infections typically involves follow-up durations that were limited to the short term, generally less than one month after treatment completion. This research provides context but not individual predictions regarding the durability of observed outcomes. For prophylaxis, studies observed responses over defined time intervals that can extend from 6 to 12 months, with some extended observation periods reported afterwards.

Key Studies & References Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update by the Infectious Diseases Society of America (IDSA)

Frequently Asked Questions (FAQ)

Common questions about Nitrofur SR (FAQ)


Q: What is the main difference between Nitrofur SR and other antibiotics used for UTIs?

The way Nitrofur SR works is unique among many antibacterials. Official information indicates that the active component works by launching a multi-target attack against the bacteria’s essential structures (like DNA and proteins). Crucially, the medication concentrates almost entirely in the urine, resulting in a localized antimicrobial effect on the infection site but maintaining low levels in the blood and other tissues.

Q: Are there any specific dietary restrictions when using Nitrofur SR?

Official guidelines emphasize that Nitrofur SR must be taken with food or milk to help the body absorb the medicine properly and minimize stomach upset. While the product label does not list specific food restrictions, general patient information sometimes discusses the possibility of bladder irritation related to acidic foods or caffeine.

Q: Is it possible for Nitrofur SR to cause yeast infections?

As with many antibacterial drugs, official sources note the potential for the overgrowth of non-susceptible organisms. The use of any antibiotic can alter the natural balance of bacteria and may lead to secondary infections, which may include fungal infections like candidiasis (yeast infections).

Q: Are allergic reactions to Nitrofur SR common?

Nitrofurantoin is strictly contraindicated in anyone with a known hypersensitivity to the drug. While severe allergic reactions, such as life-threatening swelling or breathing difficulties, are rare, they are reactions that are typically handled by seeking prompt medical review, as noted in official patient warnings.

Q: What research supports the use of Nitrofur SR over older formulations?

The SR (Sustained-Release) capsule is designed to control the rate at which the active ingredient, nitrofurantoin, is released into the body. This is achieved by formulating the capsule with two forms of the drug, one gradually dissolved and one slowly released, with the goal of achieving sustained exposure in the urinary tract.

Q: Can Nitrofur SR affect blood sugar levels in people with diabetes?

Official product information states that nitrofurantoin may cause a false positive result for glucose in the urine when tested using specific laboratory methods. This does not indicate a true change in blood sugar levels. Regulatory documents include a caution regarding use in patients with pre-existing conditions such as diabetes mellitus.

Q: Does Nitrofur SR interact with common antacids like Tums?

Antacids containing magnesium trisilicate are known to significantly reduce the absorption of nitrofurantoin, which can lower its effectiveness, and concurrent use should be avoided. Professional review is indicated when considering concurrent use with other magnesium-containing products.

Q: How is Nitrofur SR generally tolerated by most patients?

Regulatory documents classify the most commonly reported adverse effects, which typically involve the stomach and intestines. These common issues include nausea, vomiting, gas, and diarrhea, along with reports of headache.

Q: What if I experience stomach upset after taking Nitrofur SR? (General information)

Gastrointestinal upset, including nausea and vomiting, is noted in official sources as a common side effect of this medicine. The official administration requirement specifies taking the medicine with food or milk, which is often intended to mitigate these common gastrointestinal symptoms.

Q: Does Nitrofur SR affect kidney function over time?

The medicine is strictly contraindicated in patients who already have significant renal impairment (poor kidney function). Official documentation indicates that monitoring of renal function is advised during prolonged therapy, especially for those with pre-existing risk factors, but it does not state that the drug is known to cause damage to normal kidneys over time.

Q: Is Nitrofur SR suitable for people with a history of liver issues?

Official warnings indicate that nitrofurantoin can cause serious liver reactions, including chronic active hepatitis and hepatic necrosis, which may be fatal. Official product information notes that patients with a history of liver conditions may require professional review prior to use, which may include closer monitoring.

Q: Why is the time of day I take Nitrofur SR sometimes considered important?

Official dosing instructions often advise taking the medication twice daily, with approximately 12 hours between each dose (e.g., morning and evening). This specific schedule is used to achieve sustained levels of the antibacterial agent in the urinary tract throughout the day and night.

Q: What research has been done on the safety of Nitrofur SR in different age groups?

Regulatory documents define specific population contraindications, noting that the medicine is prohibited for infants under one month old and for pregnant patients at term. Official warnings also note that older adults may have an increased susceptibility to chronic pulmonary and liver reactions.

Q: Does Nitrofur SR lose its effectiveness over time (resistance)?

Regulatory data indicates that the development of bacterial resistance to nitrofurantoin has not been a significant clinical concern. This is often attributed to the drug’s multi-target mechanism, which makes it structurally difficult for bacteria to develop acquired resistance.

Q: Are there specific food types that are known to interfere with Nitrofur SR absorption?

Official guidelines state that Nitrofur SR is administered with food or milk to support absorption. The absorption is specifically known to be reduced by certain antacids that contain magnesium trisilicate.

Q: Why does Nitrofur SR sometimes cause urine to change color?

According to official patient information leaflets, it is common for nitrofurantoin to cause the urine to turn a harmless brown or yellow color. This is a normal physiological effect of the medicine and is not a cause for concern.

Q: Can Nitrofur SR affect my ability to drive or operate machinery?

Neurological adverse effects, such as dizziness and drowsiness, have been reported in official product information. Official product information indicates that driving or operating machinery should be avoided if an individual experiences these neurological adverse effects.

Q: What types of over-the-counter pain relievers are generally safe to use with Nitrofur SR?

Official sources indicate that common over-the-counter pain relievers like acetaminophen or ibuprofen are not known to interact directly with nitrofurantoin. The concurrent use of any medications, even OTC products, is a matter that requires professional review.

Q: Is the dizziness or drowsiness linked to Nitrofur SR a common problem?

Dizziness and drowsiness are noted in regulatory documents as reported adverse reactions affecting the nervous system. While their frequency is not classified as 'very common,' they are officially listed side effects associated with the drug's use.

Q: Are there different strengths of Nitrofur SR available?

According to official dosage and administration information, the sustained-release capsule formulation of Nitrofur SR is available as a 100 mg strength dose.

Q: Is Nitrofur SR effective against all common types of UTI bacteria?

Official documents state that the drug is indicated for use against susceptible strains of specific organisms commonly associated with UTIs, such as Escherichia coli, Enterococci, and Staphylococcus aureus. It is noted that the medicine is typically not active against most strains of Proteus or Pseudomonas species.

Q: What are the common reasons Nitrofur SR would be prescribed instead of another medicine?

Official guidelines and medical consensus often position Nitrofur SR as a first-line treatment for uncomplicated urinary tract infections. This preference is often due to its characteristic of concentrating heavily in the urine and its historically low rates of bacterial resistance.

Q: Can women use Nitrofur SR while breastfeeding?

Official regulatory information states that small amounts of the medicine pass into breast milk, and it can be used while breastfeeding if the baby is healthy. Use is restricted or contraindicated if the baby has jaundice or a known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Q: Can Nitrofur SR cause changes in sleep patterns?

Drowsiness is a reported neurological adverse reaction that is officially documented. Other effects on the central nervous system, such as confusion or depression, have also been reported on rare occasions.

Q: Is it normal to feel more tired while taking Nitrofur SR?

Official adverse reaction reports list tiredness (fatigue), weakness (asthenia), and drowsiness as potential effects associated with the use of this medicine.

Q: Can Nitrofur SR cause joint pain or muscle aches?

Regulatory documents note that adverse reactions associated with this medicine have included muscle aches and joint pain. Additionally, symptoms resembling a lupus-like syndrome have also been reported.

How should Nitrofur SR be stored and disposed of?

How to Store and Dispose of Nitrofur SR

Official regulatory documents define strict conditions for the storage and disposal of Nitrofur SR (Nitrofurantoin Monohydrate/Macrocrystals).

Storage Requirements

Requirement Official Condition
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the capsules in a tight, light-resistant container, tightly closed, and away from excess heat and moisture.
Child Safety Keep out of reach of children.

Disposal Instructions

Unused or expired medication should be disposed of via a formal drug take-back program when available. If a take-back program is not accessible, the product may be discarded in the household trash after mixing it with an unappealing substance, such as dirt or used coffee grounds, and sealing the mixture in a bag. Regulatory instructions specifically state that this medication must not be flushed down the toilet or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nitrofur SR found in:

A-Z Index: